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appearance (see table). In these cases, increased D50 values 
were found since the frequency of response was reduced. 
 
 
 
 
 
Conclusion: Radiologic injuries were frequently found in 
follow-up CT scans after RT for NSCLC patients. Logistic 
relationships between the risk of a radiologic response and 
increasing mean lung dose were observed both when 
categorizing the lung injuries in terms of appearance and 
when combining the categories. 
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Purpose or Objective: Although many studies have 
confirmed the synergic effects of combining chemotherapy 
and radiotherapy (RT), clinical data evaluating safety and 
efficacy of erlotinib in combination with RT in locally 
advanced non-small-cell lung carcinoma (NSCLC) are limited. 
This is the first study to determine the feasibility, 
tolerability, and efficacy of the concurrent addition of 
erlotinib to the standard conformal thoracic RT in patients 
with unresectable or locally advanced NSCLC who are not 
candidates for receiving standard CT by any cause. 
 
Material and Methods: 90 patients (p) with irresectable 
NSCLC (I-IIIB stage), ECOG < 2 and measurable disease for 
criteria RECIST were randomized. P assigned to the arm A 
received RT 3D (66 Gy/33 fractions) and P in the arm B 
received the same RT with erlotinib 150 mg/d p.o. 
concurrent up to a maximum of 6 months. The principal aim 
was the G 3-4 toxicity the secondary aims: OS, PFS, cause-
specific survival (CSS), and objective response rate (ORR). 
 
Results: 90 p were included (30 in arm A, 60 in B), 89 were 
valid for safety analysis and 81 of efficacy. Responses: CR 
A/B (%): 21,4/ 41,5 (p <0,05). Median of follow-up 17,1 m. 
OS: 15,3/ 12,9 m (p: NS). CSS: 17,7/ 21,4 m (p: NS). G 3-4 
toxicities: A/B (%): pneumonitis: 10,6/3,3; radiodermitis: 
3/3,3); esofagitis: 0/0; pulmonary fibrosis: 0/3,3; 
cardiopathy: 3,4/1,6; rash: 0/13,3; diarrhea: 3,4/6,7; 
fatigue: 0/8,3. Erlotinib did not increase the toxicity 
produced by the RT. 
 
Conclusion: The combination of erlotinib with RT produces a 
scarce clinical benefit in this group of patients, limited to 
complete responses and longer CSS rate compared with RT 
alone. Increased toxicity events were associated with 
combined therapy, mainly cutaneous toxicity. Further studies 
in molecularly unselected lung cancer patients treated with 
EGFR TKIs and radiotherapy are not indicated. Use of 
predictive biomarkers to identify patients most likely to 
benefit are mandatory 
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Purpose or Objective: To evaluate the sites of relapse and 
prognostic factors of outcome in a retrospective series of 
patients with epithelial thymic tumors (ETT) treated 
consecutively with surgery and post operative RT. 
 
Material and Methods: Data from 134 ETT patients who were 
operated according to guidelines in different centres and 
received RT in Gustave Roussy from 1990 to 2011 was 
retrospectively analysed. Before 1998, patients had 
radiotherapy to the thymic region as well as elective nodal 
radiotherapy (ENRT) to the mediastinum and both supra-
clavicular regions. From 1999 on, patients had conformal RT 
limited to the thymic tumour bed. A 3D-conformal 
radiotherapy (CRT) with CT-based treatment planning was 
used from 1995, and Intensity Modulated Radiotherapy has 
been gradually implemented since 2010 
 
Results: Median follow-up was 8.8 years. Quality of resection 
was R0 in 75%, R1 in 22%, and R2 in 3% of patients. 16% had 
neoadjuvant chemotherapy. Classification according to 
Masaoka-Koga was: stage I/IIA in 17%, IIB in 22%, III in 28%, 
and IV in 33%. 28 patients (21%) had thymic carcinoma 
according to WHO classification. The mean (median? 
delivered dose of RT was 54 Gy (42-66) and 53% patients an 
ENRT at a dose of 45-50 Gy median dose different between 
ENI and CRT. Late toxicities were observed in 16% of patients 
(11 pneumonitis, 9 pericarditis and 6 coronaropathy) but no 
related toxic-death was reported. Considering patterns of 
relapse, there were 26 local relapses which could be 
considered in-field (46% pleura, 27% mediastinum, and 27% to 
both locations) and 42 regional relapses (88% pleura, 5% 
mediastinum, and 7% lung) resulting in a locoregional control 
(LRC) rate of 67%49% at 5/10 years. Distant control rate was 
91% at 10 years. ENI (HR: 2.3) and Masaoka-Koga 
classification > stage IIB (HR: 3.2) were associated with a 
decreased LRC in the multivariate analysis (MVA). Gender, 
age, WHO classification, PS, score, R0 status, CRT dose, and 
boost CRT Were not correlated with LRR in the MVA. The 
cause specific and overall survivals (OS) at 5 and 10 years 
were 72% and 63%, respectively (add 5 year results). PS>0 
(HR: 2.6), and Masaoka-Koga stage IV (HR: 2.1) correlated 
with a lower OS in the MVA. 
 
Conclusion: Masaoka-Koga was the main prognostic factor of 
OS and LRC in this analysis. Indications of RT should be 
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discussed within a multidisciplinary board. When adjuvant RT 
is indicated, conformal RT should be used. Patients should be 
followed up as late recurrences may occur 
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Purpose or Objective: PET/CT based radiotherapy planning 
(RTP) has been shown to improve the consistency of target 
volume delineation (TVD) in lung cancer radiotherapy, 
hopefully leading to improved local control. This study 
assesses the impact of a standardized delineation protocol 
and multiple training interventions on PET/CT based TVD in 
NSCLC. 
 
Material and Methods: Over a one year period, nuclear 
medicine physicians (NMP) and radiation oncologists (RO) 
with limited experience in PET/CT based TVD from nine 
different countries participated in a multicenter study. The 
first training intervention included a three-day training 
course, consisting of three contouring assignments which 
formed the basis of a teaching discussion with the aim of 
identifying and correcting misinterpretations of practical 
guidelines, and various lectures on PET/CT based RTP. The 
second training event contained detailed individual feedback 
reports about previous performed contouring assignments and 
a webinar on PET/CT based TVD in NSCLC. Eleven teams 
consisting of a RO and NMP performed joint gross tumor 
volume (GTV) delineation of the primary tumor as per a 
standardized delineation protocol. In-house developed 
software called Big Brother recorded any user-software 
interaction, consequently allowing visual inspection of 
delineation strategies. Six delineation cases were performed 
before, during and after the training program and were 
compared with agreed expert contours (GTVexp) to assess 
delineation performance. 
 
Results: Following the three-day training course overall 
concordance indices for 3 repetitive cases increased from 
0.57±0.11 (SD) to 0.66±0.10. Observer volumes were larger 
after the training and miss of GTVexp was significantly 
reduced from 79.01±52.35 cc (SD) to 42.86±38.08 cc. Results 
are summarized in table 1. After further feedback and the 
webinar overall concordance indices for another 3 repetitive 
cases increased from 0.64±0.10 (SD) to 0.80±0.08. A 
reduction of GTVexp miss from 78.89±44.51 cc (SD) to 
30.87±20.26 cc was observed.  
 
Conclusion: Following a training intervention, PET/CT based 
TVD in NSCLC RTP using a standardized delineation protocol 
led to significant improvement in delineation performance. A 
greater improvement in TVD with the use of multiple training 
events as compared to a single training event was observed. 
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Purpose or Objective: High radiotherapy dose to the heart 
increase the risk of cardiac morbidity and death in early 
stage breast cancer and lymphoma. Recent reports (1,2) have 
indicated that an association between overall survival and 
dose to heart (e.g. V5 for the heart) are observable after 
radiotherapy of NSCLC patients as well. The objective of this 
study was to evaluate if overall survival was affected by high 
V5 to the heart in NSCLC patients treated with definitive 
radiotherapy (RT).  
1) Bradley et al, Lancet Oncology 2015 Feb;16(2):187-99. 2) 
Belderbos et al, WCLC2015 mini33.03) 
 
Material and Methods: In a single institution, 297 NSCLC 
patients were treated consecutively with definitive RT from 
2001-2007 with at least 60 Gy. Concomitant chemotherapy 
was not part of the standard treatment initially but became a 
treatment option later in the study period (weekly 
docetaxel). RT was delivered as 3D RT without elective nodal 
irradiation. No constraint on dose to the heart was applied 
during treatment planning. The heart was delineated 
retrospectively and heart doses were extracted from the 
treatment planning system (mean heart dose (MHD) and V5). 
Patients were stratified in two groups depending on their 
heart dose being above or below the median value. Survival 
test was performed using Kaplan Meyer and log-rank test. All 
patients were followed to death. 
 
Results: Patient and treatment characteristics are 
summarized in table 1. Median follow-up was 127 months. 
The overall median survival was 19.1 months with 1, 2 and 5 
year survival of 69%, 41%, and 17%, respectively. Median V5 
for the heart was 49%. No association between survival and 
heart dose were observed (p=0.29 see Fig 1). The same was 
true when including smoking, gender, and concomitant 
chemotherapy as strata in the analyses. Median MHD was 14 
Gy. Survival for patients with MHD ≥14 Gy or <14 Gy was 17% 
and 21%, respectively (p=0.83). 
